TransMedics Group, Inc.
TMDX
$68.94
$0.090.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.18% | 32.18% | 32.24% | 37.68% | 48.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.18% | 32.18% | 32.24% | 37.68% | 48.21% |
| Cost of Revenue | 31.57% | 35.76% | 23.65% | 34.94% | 49.94% |
| Gross Profit | 14.66% | 29.72% | 39.00% | 39.46% | 47.14% |
| SG&A Expenses | 44.38% | 9.67% | 7.87% | 2.78% | 20.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.37% | 23.47% | 14.96% | 18.67% | 37.50% |
| Operating Income | -51.55% | 146.10% | 493.93% | 192.35% | 120.94% |
| Income Before Tax | -68.19% | 209.53% | 442.54% | 197.72% | 115.25% |
| Income Tax Expenses | 17.71% | -63,546.97% | -4,541.38% | 3,209.76% | 407.14% |
| Earnings from Continuing Operations | -71.52% | 1,436.87% | 476.83% | 186.26% | 110.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.52% | 1,436.87% | 476.83% | 186.26% | 110.56% |
| EBIT | -51.55% | 146.10% | 493.93% | 192.35% | 120.94% |
| EBITDA | -27.16% | 97.16% | 222.52% | 153.10% | 100.80% |
| EPS Basic | -72.07% | 1,408.82% | 465.34% | 179.55% | 104.57% |
| Normalized Basic EPS | -68.81% | 203.92% | 432.16% | 190.80% | 109.14% |
| EPS Diluted | -71.52% | 1,188.05% | 450.08% | 162.49% | 100.63% |
| Normalized Diluted EPS | -64.93% | 166.24% | 374.87% | 159.11% | 86.97% |
| Average Basic Shares Outstanding | 1.96% | 1.87% | 2.01% | 2.39% | 2.93% |
| Average Diluted Shares Outstanding | -9.32% | 16.24% | 14.19% | 14.94% | 15.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |